Short telomeres, but not accelerated epigenetic or proteomic age, increase fibrotic lung disease risk: Mendelian randomisation with pleiotropy dissection and independent replication

Human bodies are not static machines; they are living systems that change over time, a process we call aging. While we often think of aging as simply the passing of years, scientists have long suspected that our cells age at different speeds, and that this "biological age" might be the real driver behind many diseases. To measure this, researchers have developed several tools. Some look at chemical tags on our DNA that change as we get older, acting like a molecular clock. Others measure the length of protective caps on the ends of our chromosomes, known as telomeres, which shorten every time a cell divides. The idea is that if we can measure how fast a person is aging biologically, we might be able to predict or even prevent diseases that strike later in life, such as autoimmune disorders where the body attacks itself, or lung diseases that scar the tissue.

For years, a popular theory suggested that accelerated biological aging was a general cause for a wide range of these immune-related diseases. If this were true, it would mean that slowing down the aging process itself could be a universal cure. However, proving this is difficult because people who are biologically older also tend to have different lifestyles, environments, and genetic histories, all of which can confuse the results. To cut through this confusion, a researcher named Sten Hanke set out to test these ideas with extreme precision, using a method that relies on genetics to act as a natural experiment. By looking at the genetic blueprints people are born with, which cannot be changed by lifestyle or environment, the study could determine if aging actually causes disease, or if the two are just happening to occur together by chance.

The study focused on six different ways to measure biological aging and tested them against six different immune-mediated diseases, creating a total of thirty-six possible connections to investigate. The diseases ranged from giant cell arteritis, which causes inflammation in blood vessels, to various forms of inflammatory bowel disease and interstitial lung disease, a condition where the lungs become stiff and scarred. The researchers used a massive amount of genetic data from hundreds of thousands of people to see if the genetic variants that make a person biologically older also made them more likely to develop these specific illnesses. They ran the numbers in both directions: checking if aging caused disease, and checking if having the disease made a person biologically older.

The results were surprisingly specific. Out of all the thirty-six combinations tested, only one connection held up to rigorous scrutiny. The study found that having shorter telomeres, which is a sign of older biological age, directly increases the risk of developing fibrotic lung disease. This is a condition where the lung tissue becomes thick and scarred, making it hard to breathe. The evidence was so strong that it held true even when the researchers looked at different populations, including people of European and East Asian ancestry, and even when they used different definitions of the disease. The shorter the telomeres, the higher the risk of the lung scarring. This confirmed that telomere length is not just a marker of aging but a direct cause of this specific lung problem.

However, the study also ruled out a much broader theory that many scientists had hoped to be true. The research found that none of the other five measures of biological aging—including the DNA-methylation clocks that track chemical changes on our genes—had any causal effect on any of the six diseases tested. This means that the idea of a single "aging clock" that drives all immune diseases is incorrect. The different ways of measuring aging are not interchangeable; just because one measure (telomere length) causes a problem does not mean the others do. In fact, the study showed that the other aging measures had no detectable impact on these diseases at all, suggesting that the link between aging and disease is far more complex and specific than previously thought.

A crucial part of the discovery involved understanding exactly why short telomeres cause lung disease. Previous studies had used a small set of genetic tools that happened to be located near genes responsible for maintaining telomeres. This made it difficult to tell if the lung disease was caused by the short telomeres themselves, or by the genes that were supposed to keep them long. Hanke's study used a much larger set of genetic tools and carefully removed the ones linked to those specific maintenance genes. Even after removing them, the link between short telomeres and lung disease remained strong. This proved that the damage comes from the telomeres themselves, not from the machinery that builds them. It also revealed that some of the earlier, stronger estimates of this risk were inflated because they included a few genetic variants that affected the lungs through a different, direct pathway, separate from the telomere length.

The study also looked at whether the gut microbiome, the community of bacteria living in our intestines, might influence lung disease by changing our telomere length. While some theories suggested that gut bacteria could speed up or slow down aging, this research found no evidence to support that chain of events. The bacteria did not appear to change telomere length in a way that would then affect the lungs. Furthermore, the study checked if having the lung disease itself could shorten telomeres, but the data was not precise enough to confirm or deny that reverse effect. The main takeaway remained clear: short telomeres are a specific cause of fibrotic lung disease, but they are not a general cause for the wide array of other immune diseases tested.

This work changes how we should think about aging and disease. It suggests that we cannot treat "biological aging" as a single, uniform force that hits all diseases equally. Instead, different aspects of aging drive different problems. For fibrotic lung disease, the length of the telomeres is the key factor, and shortening them is a direct cause of the scarring. For other conditions like arthritis or bowel inflammation, the study found no such link with the aging measures tested. This specificity is vital for future medical research. It tells scientists that trying to slow down general aging might not prevent all diseases, and that treatments for lung scarring might need to focus specifically on protecting telomeres, rather than trying to fix a general aging process that doesn't seem to be the root cause of other conditions. The findings provide a clear, evidence-based map of where aging truly matters and where it does not, moving the field away from broad assumptions toward precise, targeted understanding.